ViaCord® Collaborates with the Center for International Blood and Marrow Transplant Research®
News May 01, 2013
ViaCord, PerkinElmer’s family cord blood and tissue preservation business, is collaborating with the Center for International Blood and Marrow Transplant Research (CIBMTR) to collect, maintain and publish research from ViaCord’s cord blood stem cell transplants. This collaboration will expand knowledge of cord blood-derived stem cell applications throughout the medical and research community. To date, CIBMTR’s large network of transplant centers has resulted in the development of a clinical database of more than 30,000 cord blood transplant recipients for clinical decision-making, use in studies, and other research purposes with the goal of making a profound impact on the survival of cord blood transplant patients around the world. CIBMTR will work directly with ViaCord to collect and analyze data to better understand the quality and any outcome metrics of ViaCord’s released cord blood stem cell units as well as how the units are being used.
“Collaborating with CIBMTR, which has established the industry standard for collecting data around hematopoietic cellular therapy and regenerative medicine, allows us to simultaneously gain insights into the effectiveness of the cord blood stem cell units we have released for use as well as outcomes from their clinical application,” said Morey Kraus, Chief Scientific Officer, ViaCord. “We are then able to incorporate data from our transplanted units into the larger database, which may be accessed for other CIBMTR studies by the medical and scientific community to further their research and understanding of cord blood stem cells.”
ViaCord is working with CIBMTR to collect and publish data as well as identify outcomes unique to related or autologous (stem cells from the same patient) transplants. The collaboration will also enable the analysis of umbilical cord units released for potential future use in autologous cell therapy and regenerative medicine clinical trials, including Cerebral Palsy, Type 1 Diabetes and others.
“The science of cord blood and cord tissue stem cells is growing at a rapid pace,” said J. Douglas Rizzo, M.D., M.S., Associate Scientific Director, CIBMTR. “We are excited to collaborate with ViaCord to provide data and analytic expertise that will assist the development of the field through research.”
ViaCord's family cord blood banking services currently offers expectant families the opportunity to preserve their baby's umbilical cord blood for potential medical use by the child or a related family member. Families are also preserving their baby’s umbilical cord tissue because research suggests that one day these special cells may have the potential to treat medical conditions that are untreatable today. ViaCord has preserved the umbilical cord blood of more than 300,000 newborns. Twenty years ago, cord blood stem cells were used to treat just one disease, Fanconi's anemia. Today, cord blood stem cells have been used in the treatment of nearly 80 diseases, including cancers, certain blood disorders and immunodeficiencies.
Stem-Cell Niche for 10 Billion Colon Cells a DayNews
Researchers at the University of Zurich have discovered the identity of the stem-cell niche of the colon. The niche comprises special cells that activate the stem cells of the adjacent intestinal epithelium and are responsible for its continuous renewal.READ MORE